Industry Advisory Board
The Industry Advisory Board of the School of Pharmaceutical Sciences, Tsinghua University was established, and its first committee meeting was held in Beijing on October 24, 2025.The Board aims to bring together outstanding representatives from the biopharmaceutical industry, give full play to their rich industry experience and professional advantages, provide strategic guidance, resource support and cooperation opportunities for the development of the School of Pharmaceutical Sciences, Tsinghua University, promote the in-depth integration of the School’s teaching, scientific research and industry, and drive the innovation and development of China’s biopharmaceutical industry.
Board Members
As of December 2020, members of the Advisory Board include (a growing list):
-
Gerald Chan
Chairman and CEO
Morningside Group -
Feng Deng
Founding Managing Director
Northern Light Venture Capital -
Joaquin Duato
Chairman and Chief Executive Officer
Johnson & Johnson -
Yasuchika Hasegawa
Corporate Counselor, Former Chairman of the Board，and CEO
Takeda -
Anthony C. Hooper
Executive Vice President
Global Commercial Operations -
Lars Fruergaard Jørgensen
Chair
Healthcare Denmark -
Brian K. Kobilka
Professor of Molecular and Cellular Physiology
Stanford University School of Medicine -
Peter Loescher
Former CEO, Siemens
Former President, Global Human Health, Merck & Co -
Ge Li
Founder, Chairman and CEO
WuXi AppTec -
Robert W. Mahley
Founding President and President Emeritus
Gladstone Institutes -
Robert T. Nelsen
Co-founder and Managing Director
ARCH Venture Partners -
Joerg Reinhardt
Chairman of the Board
Novartis -
Peter G. Schultz
Vice Chair of the Board and CEO
The Scripps Research Institute -
Neil Shen
Global Steward, Sequoia Capital
Founding and Managing Partner, Sequoia Capital China -
Stefan Oschmann
Chairman of the Executive Board and CEO of Merck
-
Yigong Shi
President
Westlake University -
Michel Vounatsos
CEO
Biogen -
Michael Goettler
Viatris
Chief Executive Officer -
WANG Xiqin
Deputy Secretary of the Party Committee & President of Tsinghua University
Industry Advisory Board
The Industry Advisory Board of the School of Pharmaceutical Sciences, Tsinghua University was established, and its first committee meeting was held in Beijing on October 24, 2025.The Board aims to bring together outstanding representatives from the biopharmaceutical industry, give full play to their rich industry experience and professional advantages, provide strategic guidance, resource support and cooperation opportunities for the development of the School of Pharmaceutical Sciences, Tsinghua University, promote the in-depth integration of the School’s teaching, scientific research and industry, and drive the innovation and development of China’s biopharmaceutical industry.
Board Members
As of December 2025, members of the Industry Advisory Board include (a growing list):
-
Xiaodong Wang
BeiGene
Co-founder -
Bai Lu
Shanghai Academy of Natural Sciences
President -
Qinxian Jin
Changping Laboratory
Deputy Director -
Yu Xia
Akeso
Founder, Chairman, President, and Chief Executive Officer -
Jisong Cui
InnoCare Pharma
Co-founder, Chairman, and Chief Executive Officer -
Lu Huang
Morningside Ventures (China)
Managing Director -
Renhong Tang
Simcere Pharmaceutical Group
Executive Director -
Yuntao Zhang
China National Pharmaceutical Group Corporation (Sinopharm)
Chief Scientist -
Weikang Tao
Weikang Tao
Director, Vice President, and General Manager of the Global Innovative R&D System -
Xingli Wang
Fosun Pharma
Co-President -
Jifeng Duan
Pengli Biotechnology
Founder and Chairman
